Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
ASX Faces Legal Action Over Failed Blockchain CHESS Project 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
US Judge Dismisses Gautam Adani Criminal Charges 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Add as a preferred source on Google
Leading pharmaceutical giants Pfizer and AstraZeneca have unveiled significant investment plans for France, totaling almost $1 billion. These announcements were made in anticipation of the annual 'Choose France' business summit, signaling a robust vote of confidence in the French economy by two of the world's foremost healthcare companies.
Pfizer's Pledge to French R&D
MSN reported that Pfizer has committed to investing 500 million euros ($538.5 million) in France, focusing on enhancing its research and development (R&D) capabilities within the country. This move aims to solidify France's position as a key player in the global healthcare research landscape, significantly boosting the local economy and job market.
AstraZeneca's Dunkirk Investment
Similarly, AstraZeneca announced an investment of $388 million to develop its Dunkirk site. This financial infusion is expected to expand the company's manufacturing and production capacities in France, further establishing the country as a critical hub in AstraZeneca's international operations.
The 'Choose France' Initiative
CNBC noted that these announcements arrived just as President Emmanuel Macron was gearing up to inaugurate the 'Choose France' event on Monday. Aiming to attract major overseas businesses and investors, the initiative underscores France's ambition to strengthen its appeal as a global business and investment destination.
Earlier statements also highlighted Morgan Stanley's creation of 100 new jobs in Paris and commitments from other international firms, such as German aviation innovator Lilium.
France's Global Business Ambition
Under President Macron's leadership, France is keen to enhance its stature as a premier European business capital, competing against traditional heavyweights like New York and London. Despite Paris's 14th place ranking in the recent Z/Yen global financial centers survey, these substantial investments by Pfizer and AstraZeneca are poised to contribute significantly to France's ambition of climbing the ranks as a top destination for global finance and business.
Photo: Pfizer Newsroom
